Biogen (BIIB) EBIT Growth (3y) (2012 - 2026)
Biogen (BIIB) EBIT Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.09% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 12.54% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 51.64% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 19.17% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 8.81% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 9.40% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -102.00% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 39.22% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -37.78% |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | -96.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -96.48% |
| Mar 31, 2026 | -8.06% |
| Dec 31, 2025 | -48.19% |
| Sep 30, 2025 | -28.66% |
| Jun 30, 2025 | -43.86% |
| Mar 31, 2025 | -36.10% |
| Dec 31, 2024 | -35.67% |
| Sep 30, 2024 | -30.77% |
| Jun 30, 2024 | -32.00% |
| Mar 31, 2024 | -27.64% |
| Dec 31, 2023 | 33.63% |
| Sep 30, 2023 | -39.88% |
| Jun 30, 2023 | -61.19% |
| Mar 31, 2023 | -28.53% |
| Dec 31, 2022 | -37.22% |
| Sep 30, 2022 | -20.68% |
| Jun 30, 2022 | -26.22% |
| Mar 31, 2022 | -25.93% |
| Dec 31, 2021 | -25.90% |
| Sep 30, 2021 | -22.38% |